Navigation Links
Columbia University scientist devises new way to more rapidly generate bone tissue
Date:12/15/2008

NEW YORK (Dec. 15, 2008) Using stem cell lines not typically combined, researchers at Columbia University Medical Center have designed a new way to "grow" bone and other tissues.

The inability to foster angiogenesis a physiological process involving the growth of new blood vessels from pre-existing vessels has been a major roadblock in tissue regeneration. Previous approaches have included the use of angiogenic growth factors and the fabrication of artificial blood vessels. However, there are problems associated with these approaches. Among these problems: artificially fabricated blood vessels do not readily branch out and network with host blood vessels, and blood vessels induced by angiogenic growth factors tend to be immature and "leaky."

To overcome these obstacles, a team of Columbia researchers has co-transplanted hematopoietic and mesenchymal stem/progenitor cells to promote the regeneration of vascularized tissues. What they found was that the tissue regenerated in bone more rapidly than when either type of stem cell was used alone.

The work by Jeremy Mao, DDS, Ph.D., published today in the Public Libraries of Science, takes a new approach: rarely have mesenchymal and hematopoietic cells been delivered in combination for the healing of defects and the treatment of diseases partially due to the separate research communities in which these two cell groups are studied.

"Dr. Mao's research in tissue engineering represents the fruits of interdisciplinary science. His work has relevance for oral health care, as well as many other health care disciplines," said Dr. Ira Lamster, Dean of the Columbia University College of Dental Medicine.

Dr. Mao and colleagues demonstrated that when human mesenchymal stem/progenitor cells were seeded in micropores of 3D calcium phosphate scaffolds, followed by infusion of gel-suspended CD34+ hematopoietic cells, greater vascularization was seen in mice than when mesenchymal cells were used alone.

Furthermore, Dr. Mao's team found that the number of vessels and the diameter of the vessels produced by the co-transplantation of hematopoietic and mesenchymal to create vascularized tissue were dramatically increased when combined with Vascular Endothelial Growth Factor or VEGF.

"The work has potential beyond bones and may have implications for the growth of muscle, nerve and organs," Dr. Mao said. "The synergistic action of mesenchymal cells and hematopoietic cells provide an alternative approach for regrowing a host of vascular tissues."


'/>"/>

Contact: Alex Lyda
mal2133@columbia.edu
212-305-0820
Columbia University Medical Center
Source:Eurekalert

Related biology news :

1. Salmon smolt survival similar in Columbia and Fraser rivers
2. Similar survival rates for Pacific salmon in Fraser, Columbia Rivers raises new questions
3. Columbia to award 2008 Horwitz Prize to Arthur Horwich & Ulrich Hartl for cellular protein folding
4. Columbia geneticists uncover new gene involved in determining hair texture and density in humans
5. Columbia researchers: Growth of CT scan use may lead to significant public health problem
6. 3 Columbia University Medical Center faculty elected to Institute of Medicine
7. Columbia to award 2007 Horwitz Prize to three generations of teacher-student scientists
8. Queens University Belfast plays leading role in Europe-wide tests for safer food
9. Wii bit of fun at Rice University has serious intent
10. Rice University study finds possible clues to epilepsy, autism
11. World Energy Outlook to be presented at Rice University Dec. 9
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 8.8% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:3/20/2017)... , March 20, 2017 PMD Healthcare ... personal spirometer and Wellness Management System (WMS), a remote, ... Founded in 2010, PMD Healthcare is a Medical Device, ... a mission dedicated to creating innovative solutions that empower ... With that intent focus, PMD developed the first ever ...
(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today ... to uncover insights to support its reporting, help direct future ... UK,s leading youth charity will be using Brandwatch Analytics social listening ... better understanding of the topics and issues that are a priority ... ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... to accelerating the fight against cancer, autoimmune disease and more through a single-cell ... single-cell metabolomics and proteomics analysis platform developed in the laboratory of Dr. ...
(Date:3/27/2017)... March 27, 2017 Infectex Ltd., a Russian portfolio company of ... study of SQ109 added to the standard drug therapy regimen in patients with multidrug-resistant ... Sequella, Inc. ( USA ) and the US National Institutes of Health. ... ... Biotech Venture Fund Logo ...
(Date:3/27/2017)... , March 27, 2017 The ... to a comprehensive library of reports on Valero Energy ... transportation fuels and petrochemical industries. ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO) ... biofuel production to go green. Ethanol today, even though touted ...
(Date:3/27/2017)... -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, ... Welch , will be presenting at this year,s MicroCap ... at the Essex House in New York ... Mark Erlander , Ph.D., will also be available ... The presentation will be webcast live at http://wsw.com/webcast/microcapconf3/trov ...
Breaking Biology Technology: